Since then, immune checkpoints inhibitors have been considered as novel targets for cancer immunotherapy, and several antibodies targeting CTLA4, PD-1, and PD-L1 are currently approved for use in a variety of different cancers (reviewed in [18,19]). Here, PDCD1 is linked to cancer.